BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abdelwahab S, Azmy A, Abdel-aziz H, Salim H, Mahmoud A. Anti-EGFR (cetuximab) combined with irinotecan for treatment of elderly patients with metastatic colorectal cancer (mCRC). J Cancer Res Clin Oncol 2012;138:1487-92. [DOI: 10.1007/s00432-012-1229-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Dotan E, Devarajan K, D'Silva AJ, Beck A, Kloth DD, Cohen SJ, Denlinger C. Patterns of use and tolerance of anti-epidermal growth factor receptor antibodies in older adults with metastatic colorectal cancer. Clin Colorectal Cancer 2014;13:192-8. [PMID: 25074246 DOI: 10.1016/j.clcc.2014.05.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
2 Chakraborty S, Filippi CG, Wong T, Ray A, Fralin S, Tsiouris AJ, Praminick B, Demopoulos A, Mccrea HJ, Bodhinayake I, Ortiz R, Langer DJ, Boockvar JA. Superselective intraarterial cerebral infusion of cetuximab after osmotic blood/brain barrier disruption for recurrent malignant glioma: phase I study. J Neurooncol 2016;128:405-15. [DOI: 10.1007/s11060-016-2099-8] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 7.3] [Reference Citation Analysis]
3 Papamichael D, Lopes GS, Olswold CL, Douillard JY, Adams RA, Maughan TS, Van Cutsem E, Venook AP, Lenz HJ, Heinemann V, Kaplan R, Bokemeyer C, Chibaudel B, Grothey A, Yoshino T, Zalcberg J, De Gramont A, Shi Q. Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥ 70 years. Eur J Cancer 2022;163:1-15. [PMID: 35033994 DOI: 10.1016/j.ejca.2021.12.007] [Reference Citation Analysis]
4 Matikas A, Asimakopoulou N, Georgoulias V, Souglakos J. The place of targeted agents in the treatment of elderly patients with metastatic colorectal cancer. Cancers (Basel) 2015;7:439-49. [PMID: 25782007 DOI: 10.3390/cancers7010439] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
5 Feliu J, Salud A, Safont MJ, García-Girón C, Aparicio J, Vera R, Serra O, Casado E, Jorge M, Escudero P, Bosch C, Bohn U, Pérez-Carrión R, Carmona A, Martínez-Marín V, Maurel J. First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study. Br J Cancer 2014;111:241-8. [PMID: 24946000 DOI: 10.1038/bjc.2014.346] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
6 Moth EB, Vardy J, Blinman P. Decision-making in geriatric oncology: systemic treatment considerations for older adults with colon cancer. Expert Rev Gastroenterol Hepatol 2016;10:1321-40. [PMID: 27718755 DOI: 10.1080/17474124.2016.1244003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
7 Aparicio T, Canouï-Poitrine F, Caillet P, François E, Cudennec T, Carola E, Albrand G, Bouvier AM, Petri C, Couturier B, Phelip JM, Bengrine-Lefevre L, Paillaud E. Treatment guidelines of metastatic colorectal cancer in older patients from the French Society of Geriatric Oncology (SoFOG). Dig Liver Dis 2020;52:493-505. [PMID: 32029404 DOI: 10.1016/j.dld.2019.12.145] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
8 Martinelli E, Cardone C, Troiani T, Normanno N, Pisconti S, Sforza V, Bordonaro AR, Rachiglio AM, Lambiase M, Latiano TP, Modoni G, Cordio S, Giuliani F, Biglietto M, Montesarchio V, Barone C, Tonini G, Cinieri S, Febbraro A, Rizzi D, De Vita F, Orditura M, Colucci G, Maiello E, Ciardiello F, Iaffaioli V, Nasti G, Nappi A, Botti G, Tatangelo F, Chicchinelli N, Montrone M, Sebastio A, Guarino T, Simone G, Graziano P, Chiarazzo C, Maggio G, Longhitano L, Manusia M, Cartenì G, Nappi O, Micheli P, Leo L, Rossi S, Cassano A, Tommaselli E, Giordano G, Sponziello F, Marino A, Rinaldi A, Romito S, Muda AO, Lorusso V, Leo S, Barni S, Grimaldi G, Aieta M. Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial. ESMO Open 2016;1:e000086. [PMID: 28848656 DOI: 10.1136/esmoopen-2016-000086] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
9 Rosati G, Aprile G, Cardellino GG, Avallone A. A review and assessment of currently available data of the EGFR antibodies in elderly patients with metastatic colorectal cancer. Journal of Geriatric Oncology 2016;7:134-41. [DOI: 10.1016/j.jgo.2016.01.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
10 Mccleary NJ, Dotan E, Browner I. Refining the Chemotherapy Approach for Older Patients With Colon Cancer. JCO 2014;32:2570-80. [DOI: 10.1200/jco.2014.55.1960] [Cited by in Crossref: 33] [Cited by in F6Publishing: 14] [Article Influence: 4.1] [Reference Citation Analysis]
11 Yang Y, Lin J, Chen W, Lin T, Yang S, Jiang J, Lan Y, Lin C, Yen C, Tzeng C, Teng H. Comparison of cetuximab to bevacizumab as the first-line bio-chemotherapy for patients with metastatic colorectal cancer: Superior progression-free survival is restricted to patients with measurable tumors and objective tumor response—a retrospective study. J Cancer Res Clin Oncol 2014;140:1927-36. [DOI: 10.1007/s00432-014-1741-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
12 Monteiro AR, Conde RS, Basto R, Sclafani F, Deleporte A, Hendlisz A, Dal Lago L. Targeted agents in older patients with gastrointestinal cancers - An overview. J Geriatr Oncol 2021:S1879-4068(21)00161-2. [PMID: 34226158 DOI: 10.1016/j.jgo.2021.06.013] [Reference Citation Analysis]